New NASH pill tested in humans for first time

NCT ID NCT06308861

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new oral drug called J2H-1702 in 100 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a type of liver disease. The study was completed and used a placebo for comparison.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

J2H-1702 (oral tablet)

What this could lead to

If successful, this could lead to a new oral treatment option for non-alcoholic steatohepatitis (NASH), a serious liver disease.

What could go wrong

This is a very early Phase 1 trial in only 100 healthy men, not patients. It primarily checks safety, not whether the drug works for NASH. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • J2H Biotech

    Suwon, Gyeonggi-do, 16684, South Korea